Triple-Drug cocktail shows promise against CLL

NCT ID NCT02427451

Ongoing Disease control Sponsor: Kerry Rogers Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination works. About 87 participants will receive the drugs to control the disease and reduce cancer cells to undetectable levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Obinutuzumab, ibrutinib, and venetoclax
What this could lead to: If successful, this combination could offer a more effective treatment option for CLL, potentially leading to longer remission without the need for continuous therapy.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants. The combination may cause significant side effects, and it is not yet known if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.